share_log

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya與葛蘭素史克合作提名潛在的一流Pol Theta解旋酶抑制劑
Benzinga Real-time News ·  2022/06/28 21:20
  • Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. 
  • Ideaya is collaborating with GSK plc (NYSE:GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with BRCA or other homologous recombination mutations or homologous recombination deficiency. 
  • The companies are targeting an IND submission for the Pol Theta Helicase DC in the first half of 2023.
  • Also Read: Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial.
  • GSK will lead clinical development for the Pol Theta program. It holds a global license to develop and commercialize the Pol Theta Helicase candidate. It is responsible for all R&D costs for the program, including those incurred by IDEAYA. 
  • IDEAYA is eligible to receive a milestone payment of up to $485 million.
  • Upon potential commercialization, IDEAYA will be eligible to receive up to $475 million of commercial milestones.
  • Price Action: IDYA shares closed at $13.61 on Monday, and GSK stock is up 0.16% at $43.77 during the premarket session on the last check Tuesday.
  • Ideaya生物科學公司納斯達克(Sequoia Capital：IDYA)選擇了一種潛在的一流Pol Theta解旋酶開發候選者，這是一種DNAPolymerase Theta解旋酶域的小分子抑制劑。
  • Ideaya 正在與葛蘭素史克(紐約證券交易所股票代碼：GSK)關於IND使能研究支持Pol Theta解旋酶候選與GSK的PARP抑制劑niraparib聯合治療BRCA或其他同源重組突變或同源重組缺陷的腫瘤的評估。
  • 這兩家公司的目標是在2023年上半年為Pol Theta解旋酶DC提交IND。
  • 另請閲讀： IDEAYA生物科學公司的IDE397在早期實體瘤試驗中顯示出初步耐受性.
  • 葛蘭素史克將領導Pol Theta計劃的臨牀開發。它擁有開發Pol Theta解旋酶候選並將其商業化的全球許可證。它負責該項目的所有研發費用，包括IDEAYA產生的費用。
  • IDEAYA有資格獲得高達4.85億美元的里程碑付款。
  • 在潛在的商業化後，IDEAYA將有資格獲得高達4.75億美元的商業里程碑。
  • 價格行動：IDYA股價週一收於13.61美元，葛蘭素史克股價週二盤前上漲0.16%，至43.77美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論